|
JUST OUT !
(Preview)
http://blogs.scientificamerican.com/absolutely-maybe/2014/10/10/the-hepatitis-c-escalation-baby-boomer-ripple-effects/
|
Huey
|
0
|
652
|
|
|
|
|
Let Them Eat Cake
(Preview)
The French are not happy about Gilead's pricing and they intend to do something about it. "The government will selectively tax drugmakers when the total cost to the state from their hepatitis C drugs exceeds a certain amount each year, " http://hepatitiscnewdrugs.blogspot.com/20...
|
Isiscat2011
|
0
|
663
|
|
|
|
|
Hiv Dance
(Preview)
http://medicalxpress.com/news/2014-10-real-dynamic-motion-hiv-readies.html
|
Huey
|
0
|
690
|
|
|
|
|
First all oral treatment for Japan
(Preview)
Great news for our Japanese members! "Bristol-Myers Squibb announced in July that the Japanese Ministry of Health, Labor and Welfare approved daclatasvir, a potent, pan-genotypic NS5A replication complex inhibitor, and asunaprevir, an NS3/4A protease inhibitor, for patients with hep...
|
Tig
|
0
|
861
|
|
|
|
|
New Abbvie Patient Assistance Hep C Website
(Preview)
Abbvie has in tandem with their latest television advertising program, developed/sponsored a new patient assistance website. It's designed to help people understand and provide individual help on treatment possibilities. I thought those that have missed it or haven't seen the on air and onlin...
|
Tig
|
2
|
1571
|
|
|
|
|
New AASLD Guidelines for Monitoring Patients
(Preview)
On September 24th the AASLD added new guidelines for monitoring HCV patients who are starting tx, on tx, or have completed tx. Here it is: http://www.hcvguidelines.org/node/92
|
Isiscat2011
|
1
|
933
|
|
|
|
|
AASLD Annual Meeting
(Preview)
In a little over 5 weeks the AASLD will be holding its annual liver meeting in Boston. This conference will be well attended by Hepatologists and all of the major pharmas will be presenting -- probably some new HCV tx data. This is good news for HCV patients as our docs will acquire, or at least have acce...
|
Isiscat2011
|
2
|
772
|
|
|
|
|
ABBVie Combo
(Preview)
There is a rumor going around that the Abbvie combo, which was scheduled for FDA review in December of 2014, is no longer on the approval review calendar for this year. I checked the FDA review calendar and it appears to be true. Anybody know anything about this? A significant development if true.
|
Isiscat2011
|
8
|
1221
|
|
|
|
|
Simeprevir (Olysio) draft recommendations by NICE (UK)
(Preview)
NICE consults on draft guidance on the drug simeprevir (Olysio) for treating hepatitis C17 Sept 2014 - In draft guidance published today healthcare guidance body NICE has recommended simeprevir (Olysio, Janssen) as a treatment option for some people with chronic hepatitis C. The draft guidance...
|
Cinnamon Girl
|
6
|
1437
|
|
|
|
|
activest
(Preview)
http://www.thebody.com/content/74888/act-up-calls-on-congress-for-price-cut-on-sovaldi-.html
|
Huey
|
3
|
1081
|
|
|
|
|
Gileads Harvoni (Ledipasvir/Sofobuvir)
(Preview)
European CHMP Adopts Positive Opinion for Gilead's Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults FOSTER CITY, Calif., Sep 26, 2014 (BUSINESS WIRE) -- Gilead Sciences, Inc.GILD, +0.97% today announced that the Committee for Medicinal Produ...
|
suziq
|
4
|
2263
|
|
|
|
|
New DAA Phase 3 Studies for genotype 1 at EASL
(Preview)
While looking for other information on study results, I came across this report and wasn't sure if it had be shared here on the forum yet. To avoid losing it I will post it for everyone's review. It has a wealth of additional reference sites, etc. and think some of you will find it worthy of a bookmark! New...
|
Tig
|
0
|
600
|
|
|
|
|
new methods
(Preview)
Mice treated with the antibody genetic code resisted becoming infected with hepatitis C when they were exposed to the virus, the researchers reported in the Sept. 17 issue of the journal Science Translational Medicine. The researchers also gave the antibodies to mice that already were infected a...
|
Huey
|
0
|
673
|
|
|
|
|
hepatitiscentral.com
(Preview)
http://www.hepatitiscentral.com/mt/archives/2014/09/say-it-aint-so-new-hep-c-drug-to-surpass-84000.html?eml=hepcen217
|
Josh Haynie
|
0
|
970
|
|
|
|
|
Gilead announces generic licensing agreements
(Preview)
http://www.gilead.com/news/press-releases/2014/9/gilead-announces-generic-licensing-agreements-to-increase-access-to-hepatitis-c-treatments-in-developing-countries
|
Liamc
|
5
|
1298
|
|
|
|
|
S/L Combo Pricing Guesstimates
(Preview)
For what it's worth... "Gregg Alton, Gilead's executive vice president of corporate and medical affairs, declined to give an exact price for the new medicine, the first all-oral treatment for the virus which is expected to launch next month. The total cost of the current treatment is $95,00...
|
OldenSlow
|
4
|
1068
|
|
|
|
|
NICE (Uk) Draft Recommendation for Sofosbuvir: Key Points
(Preview)
Key Points: NICE draft recommendation for SofosbuvirPLEASE NOTE: This is draft guidance; NICE has not yet issued final guidance to the NHS What is recommended for treatment on the NHS?Sofosbuvir, interferon and ribavirin for adults with:Genotype 1Genotype 3 with cirrhosisGenotype 3 who have p...
|
Cinnamon Girl
|
7
|
2025
|
|
|
|
|
European Commission Approves Daklinza (daclatasvir) Across Multiple Genotypes
(Preview)
Wednesday, August 27, PRINCETON, N.J. - Bristol-Myers Squibb today announced that the European Commission has approved Daklinza (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor, for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 fo...
|
Cinnamon Girl
|
2
|
1098
|
|
|
|
|
Sovaldi in Australia
(Preview)
Looks like Sovaldi is too expensive for Australians according to the government? http://www.gastroenterologyupdate.com.au/latest-news/sofosbuvir-and-vedolizumab-knocked-back
|
longld
|
4
|
1351
|
|
|
|
|
September edition HCV Advocate Newsletter
(Preview)
For those who are interested. http://www.hcvadvocate.org/news/NewsUpdates_pdf/Advocate_2014/advocate0914.pdf
|
mallani
|
0
|
681
|
|
|
|
|
Potential Resistance Pathways for Sofosbuvir
(Preview)
"SOF has a high barrier to resistance; however, low frequency NS5B substitutions associated with treatment failure were identified that may contribute to resistance of this important drug for chronic HCV infection." [url]http://hepatitiscnewdrugs.blogspot.com/2014/08/cli...
|
OldenSlow
|
16
|
1644
|
|
|
|
|
RIP Incivek
(Preview)
New Hep C Drugs Lead to Cancellation of Vertexs Incivek Following the release of newer, improved therapies to treat hepatitis C virus (HCV), Vertex Pharmaceuticals has decided to discontinue Incivek (telaprevir), The Wall Street Journal reports. Vertex announced in an August 11 letter to phys...
|
Gator Man
|
15
|
1256
|
|
|
|
|
motley fool
(Preview)
Recs 2 Back to Yahoo!Should Gilead Sciences, inc. Fear This New Competitor Drug?By Todd Campbell | More Articles | Save For Later August 26, 2014 | According to ViiV Healthcare -- GlaxoSmithKline (NYSE: GSK ) , Pfizer (NYSE: PFE ) , and Shionogi's HIV drug consortium -- one in thre...
|
Huey
|
0
|
807
|
|
|
|
|
UK to demand price for Sovaldi
(Preview)
http://www.reuters.com/article/2014/08/14/us-health-hepatitis-gilead-sciences-idUSKBN0GE2G420140814?feedType=RSS&feedName=healthNewshepatitis C pill Sovaldi for chronically ill patients although at...
|
longld
|
6
|
1772
|
|
|
|
|
WSJ The Medical Innovation Threat
(Preview)
http://online.wsj.com/articles/the-medical-innovation-threat-14084...
|
longld
|
0
|
2269
|
|
|
|
|
AASLD Retreatment Guidelines
(Preview)
We've been discussing treatment guidelines and the fact that these guidelines are changing so rapidly they are difficult to keep up with. With that thought in mind, I located a fairly recent AASLD release that discusses the guidelines suggested for people that have failed previous treatment. As t...
|
Tig
|
0
|
693
|
|
|
|
|
This is a good summary, Lost of info here
(Preview)
Psychiatric Complications of Hepatitis C Treatment - Part 1 https://www.youtube.com/watch?v=5b7o2fBSI2M
|
Huey
|
0
|
667
|
|
|
|
|
NICE (UK) issues further draft guidelines for use of sofosbuvir within the NHS
(Preview)
NICE (the National Institute for Health and Care Excellence) consults on further draft guidance on the drug sofosbuvir (Sovaldi) for treating hepatitis C15th Aug. 2014 - In further draft guidance NICE has recommended sofosbuvir (Sovaldi, Gilead Sciences) as a treatment option for some people w...
|
Cinnamon Girl
|
0
|
892
|
|
|
|
|
GUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH HEPATITIS C INFECTION
(Preview)
If you haven't seen the April 2014 WHO (World Health Organization) HCV care and treatment guidelines, I thought you may be interested in reading their recommendations. There is a lot of interesting information. I looked for it's previous inclusion here on the forum and didn't see it. I apologize if...
|
Tig
|
4
|
1139
|
|
|
|
|
UNC Study on Viral Persistence
(Preview)
Might be of interest to some. Such a sneaky little bastard... UNC Hep C Study
|
OldenSlow
|
4
|
1084
|
|
|
